Safety and Efficacy of CD19 CAR-T/CAR-NK Cells

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 10, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Safety and Efficacy
Interventions
BIOLOGICAL

CAR-T/CAR-NK cells

One to two days after completion of eluvial chemotherapy, CAR-T/CAR-NK cells were transfused in subjects assessed by the investigators as eligible for infusion. The CAR-T/CAR-NK dose is calculated according to the patient's body weight, and the total number of cells transfused is about 1-2x106 /kg. Single intravenous infusion

Trial Locations (1)

250000

Shandong Province, Shandong

All Listed Sponsors
lead

The Second Hospital of Shandong University

OTHER